GCLLSG 2016 | Where are we with precision medicine for CLL?
John Gribben
• 16 Sep 2016
John Gribben, MD, DSc, FRCPath, FMed Sci of Barts Cancer Institute, London, UK discusses the future of precision medicine for chronic lymphocytic leukemia (CLL) at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. Prof. Gribben starts by explaining that we have the opportunity to be thinking about how we can identify that for one patient, a specific treatment may be ideal but will not be ideal for another patient. He believes that we are moving away from a one treatment fits all approach. We are not there yet but it is where doctors are hoping treatment will go and it is the focus of ongoing clinical trials at the moment.
